Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency portfolio with an additional USD $1,500,000 investment in Bitcoin (BTC) and other cryptocurrencies, following Board approval. This strategic move brings the company's total crypto investment to USD $3,500,000.
The company will continue accepting future financings and transactions in cryptocurrency, viewing it as a potential hedge against the dollar and an opportunity for shareholder returns. All crypto assets are held with a compliant custodian, and transactions adhere to financial and audit regulations. Quantum BioPharma maintains flexibility to adjust its cryptocurrency holdings based on market conditions.
Quantum BioPharma (NASDAQ: QNTM) ha ampliato il suo portafoglio di criptovalute con un ulteriore investimento di 1.500.000 USD in Bitcoin (BTC) e altre criptovalute, dopo l'approvazione del Consiglio. Questa mossa strategica porta l'investimento totale dell'azienda in criptovalute a 3.500.000 USD.
L'azienda continuerà ad accettare futuri finanziamenti e transazioni in criptovaluta, vedendola come una potenziale protezione contro il dollaro e un'opportunità per i rendimenti degli azionisti. Tutti gli asset in criptovaluta sono custoditi presso un custode conforme e le transazioni rispettano le normative finanziarie e di audit. Quantum BioPharma mantiene la flessibilità di adeguare le sue partecipazioni in criptovaluta in base alle condizioni di mercato.
Quantum BioPharma (NASDAQ: QNTM) ha ampliado su cartera de criptomonedas con una inversión adicional de 1.500.000 USD en Bitcoin (BTC) y otras criptomonedas, tras la aprobación de la Junta. Este movimiento estratégico lleva la inversión total de la empresa en criptomonedas a 3.500.000 USD.
La empresa continuará aceptando futuros financiamientos y transacciones en criptomonedas, viéndolo como una posible cobertura contra el dólar y una oportunidad para los rendimientos de los accionistas. Todos los activos en criptomonedas se mantienen con un custodio conforme, y las transacciones cumplen con las regulaciones financieras y de auditoría. Quantum BioPharma mantiene la flexibilidad para ajustar sus tenencias de criptomonedas según las condiciones del mercado.
Quantum BioPharma (NASDAQ: QNTM)는 이사회 승인 후 비트코인(BTC) 및 기타 암호화폐에 1,500,000 USD를 추가 투자하여 암호화폐 포트폴리오를 확장했습니다. 이 전략적 조치는 회사의 총 암호화폐 투자액을 3,500,000 USD로 늘립니다.
회사는 향후 자금 조달 및 거래를 암호화폐로 계속 수용할 것이며, 이를 달러에 대한 잠재적인 헤지로 보고 주주 수익의 기회로 활용할 것입니다. 모든 암호화 자산은 규정을 준수하는 수탁자에게 보관되며, 거래는 재무 및 감사 규정을 준수합니다. Quantum BioPharma는 시장 상황에 따라 암호화폐 보유량을 조정할 수 있는 유연성을 유지합니다.
Quantum BioPharma (NASDAQ: QNTM) a élargi son portefeuille de cryptomonnaies avec un investissement supplémentaire de 1.500.000 USD dans le Bitcoin (BTC) et d'autres cryptomonnaies, suite à l'approbation du Conseil. Ce mouvement stratégique porte l'investissement total de l'entreprise dans les cryptomonnaies à 3.500.000 USD.
L'entreprise continuera d'accepter les financements et transactions futurs en cryptomonnaies, les considérant comme une couverture potentielle contre le dollar et une opportunité pour les rendements des actionnaires. Tous les actifs cryptographiques sont conservés par un dépositaire conforme, et les transactions respectent les réglementations financières et d'audit. Quantum BioPharma conserve la flexibilité d'ajuster ses avoirs en cryptomonnaies en fonction des conditions du marché.
Quantum BioPharma (NASDAQ: QNTM) hat sein Krypto-Portfolio mit einer zusätzlichen Investition von 1.500.000 USD in Bitcoin (BTC) und andere Kryptowährungen nach Genehmigung des Vorstands erweitert. Dieser strategische Schritt bringt die Gesamtinvestition des Unternehmens in Kryptowährungen auf 3.500.000 USD.
Das Unternehmen wird weiterhin zukünftige Finanzierungen und Transaktionen in Kryptowährungen akzeptieren und sieht dies als potenziellen Schutz gegen den Dollar und als Möglichkeit für Renditen der Aktionäre. Alle Krypto-Assets werden bei einem konformen Treuhänder gehalten, und die Transaktionen entsprechen den finanziellen und auditrechtlichen Vorschriften. Quantum BioPharma behält sich die Flexibilität vor, seine Kryptowährungsbestände je nach Marktlage anzupassen.
- Additional $1.5M investment in cryptocurrencies, bringing total crypto holdings to $3.5M
- Strategic diversification of treasury assets as hedge against dollar
- Enhanced financing flexibility through cryptocurrency transaction capabilities
- Exposure to cryptocurrency market volatility risks
- Significant capital allocation to volatile digital assets
TORONTO, March 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased an additional USD
This move reflects the company's belief in the potential of Bitcoin (BTC) and other currencies to provide a return on investment for shareholders and to provide some hedge against the dollar. The company is now set up to receive financing in cryptocurrencies as well as executing other types of transactions in cryptocurrencies, improving the prospects of further financing as needed.
The company is holding all its cryptocurrency with a fully compliant custodian. The company emphasizes that all transactions are and will be fully compliant with all relevant financial and audit regulations, ensuring a secure and legal process.
The Company will continue to monitor market conditions and may increase or decrease its holdings of Bitcoin (BTC) or other cryptocurrencies as it deems appropriate.
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such.
Forward-looking information in this press release are based on certain assumptions and expected future events.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
QNTM@mzgroup.us
www.mzgroup.us
FAQ
How much has Quantum BioPharma (QNTM) invested in cryptocurrencies as of March 2025?
What is the purpose of QNTM's cryptocurrency investment strategy?
How does QNTM secure its cryptocurrency holdings?
Will QNTM continue to invest in cryptocurrencies?
